Significant advancements have been achieved in delineating the progress of the Global PROMS (PROMS) Initiative. The PROMS Initiative, a collaborative endeavor by the European Charcot Foundation and the Multiple Sclerosis International Federation, strives to amplify the influence of patient input on MS care and establish a cohesive perspective on Patient-Reported Outcomes (PROs) for diverse stakeholders. This initiative has established an expansive, participatory governance framework launching four dedicated working groups that have made substantive contributions to research, clinical management, eHealth, and healthcare system reform. The initiative prioritizes the global integration of patient (For the purposes of the Global PROMS Initiative, the term "patient" refers to the people with the disease (aka People with Multiple Sclerosis - pwMS): any individual with lived experience of the disease. People affected by the disease/Multiple Sclerosis: any individual or group that is affected by the disease: E.g., family members, caregivers will be also engaged as the other stakeholders in the initiative). insights into the management of MS care. It merges subjective PROs with objective clinical metrics, thereby addressing the complex variability of disease presentation and progression. Following the completion of its second phase, the initiative aims to help increasing the uptake of eHealth tools and passive PROs within research and clinical settings, affirming its unwavering dedication to the progressive refinement of MS care. Looking forward, the initiative is poised to continue enhancing global surveys, rethinking to the relevant statistical approaches in clinical trials, and cultivating a unified stance among 'industry', regulatory bodies and health policy making regarding the application of PROs in MS healthcare strategies.

Accelerated Cure Project Waltham MA United States

Ad Scientiam Paris Île de France France

Brain and Mind Center University of Sydney Camperdown NSW Australia

Charité Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin Experimental and Clinical Research Center Berlin Germany

Department of Biostatistics School of Public Health The University of Alabama at Birmingham Birmingham AL United States

Department of Clinical Neuroscience Neurogenetics Multiple Sclerosis Karolinska Institutet Stockholm Sweden

Department of Health Sciences University of Genoa Genoa Italy

Department of Life Science University of Siena Siena Italy

Department of Neurology Bursa Faculty of Medicine Bursa Yüksek İhtisas Training and Research Hospital University of Health Sciences Bursa Türkiye

Department of Neurology Icahn School of Medicine at Mount Sinai New York NY United States

Department of Neurology Medical University of Vienna Vienna Austria

Department of Neurology Palacky University Olomouc Olomouc Czechia

Department of Neurology Sakarya University Faculty of Medicine Sakarya Türkiye

Department of Neurology The Center for Neurological Research Næstved Slagelse Ringsted Hospitals Slagelse Denmark

Department of Neurology UKD Medical Faculty Heinrich Heine Universitat Düsseldorf Düsseldorf Germany

Department of Rehabilitation Sciences Casa di Cura Igea Milan Italy

European Medicines Agency Public and Stakeholder Engagement Department Amsterdam North Holland Netherlands

European MS Platform Brussels Belgium

Faculty of Medicine Health and Life Sciences Swansea University Swansea United Kingdom

Hasselt University Biomedical Research Institute Hasselt Belgium

Hoffmann La Roche Basel Switzerland

Hopital Vall d'Hebron Universitat Autonoma de Barcelona Barcelona Spain

Institute for Healthcare Policy KU Leuven Leuven Belgium

Institute of Regional Health Research and Molecular Medicine University of Southern Denmark Odense Denmark

Merck KGaA Darmstadt Germany

MS Lëtzebuerg Luxembourg Belgium

Multiple Sclerosis International Federation London United Kingdom

Multiple Sclerosis Society UK London United Kingdom

Multiple Sclerosis South Africa Hermanus Western Cape South Africa

National Multiple Sclerosis Society New York NY United States

Neurology Department Pitié Salpêtrière Hospital APHP Paris France

Plymouth University Peninsula Schools of Medicine and Dentistry Devon Plymouth United Kingdom

Programa de Pós Graduação Stricto Senso em Neurologia Department of Neurology Fluminense Federal University Niterói Brazil

Research Centre on Public Health University of Milan Bicocca Milan Italy

Research Department Italian Multiple Sclerosis Foundation Genoa Italy

Sorbonne Université Paris Brain Institute ICM CNRS Inserm Paris France

Université de Lille Inserm LilNCog CHU Lille FHU Precise Lille France

University of California San Francisco San Francisco CA United States

University Vita Salute San Raffaele Milan Italy

Zobrazit více v PubMed

Zaratin P, Vermersch P, Amato MP, Brichetto G, Coetzee T, Cutter G, et al. . The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: progresses and open questions. Mult Scler Relat Disord. (2022) 61:103757. doi: 10.1016/j.msard.2022.103757 PubMed DOI

Beccia F, Hoxhaj I, Castagna C, Strohäker T, Cadeddu C, Ricciardi W, et al. . An overview of personalized medicine landscape and policies in the European Union. Eur J Pub Health. (2022) 32:844–51. doi: 10.1093/eurpub/ckac103, PMID: PubMed DOI PMC

Zaratin P, Bertorello D, Guglielmino R, Devigili D, Brichetto G, Tageo V, et al. . The MULTI-ACT model: the path forward for participatory and anticipatory governance in health research and care. Health Res Policy Syst. (2022) 20:22. doi: 10.1186/s12961-022-00825-2, PMID: PubMed DOI PMC

Müller J, Cagol A, Lorscheider J, Tsagkas C, Benkert P, Yaldizli Ö, et al. . Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review. JAMA Neurol. (2023) 80:1232–45. doi: 10.1001/jamaneurol.2023.3331, PMID: PubMed DOI

Tur C, Carbonell-Mirabent P, Cobo-Calvo Á, Otero-Romero S, Arrambide G, Midaglia L, et al. . Association of Early Progression Independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis. JAMA Neurol. (2023) 80:151–60. doi: 10.1001/jamaneurol.2022.4655, PMID: PubMed DOI PMC

Tur C, Rocca MA. Progression independent of relapse activity in multiple sclerosis. Neurology. (2024) 102:e207936. doi: 10.1212/WNL.0000000000207936 PubMed DOI

Kappos L, Wolinsky JS, Giovannonim G, Arnold DL, Wang Q, Bernasconi C, et al. . Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. (2020) 77:1132–40. doi: 10.1001/jamaneurol.2020.1568, PMID: PubMed DOI PMC

Lublin FD, Häring DA, Ganjgahi H, Ocampo A, Hatami F, Čuklina J, et al. . How patients with multiple sclerosis acquire disability. Brain. (2022) 145:3147–61. doi: 10.1093/brain/awac016, PMID: PubMed DOI PMC

Satyanarayan S, Cutter G, Krieger S, Cofield S, Wolinsky JS, Lublin F. The impact of relapse definition and measures of durability on MS clinical trial outcomes. Mult Scler. (2023) 202329, 29:568–75. doi: 10.1177/13524585231157211 PubMed DOI PMC

Hegen H, Bsteh G, Berger T. ‘No evidence of disease activity’ – is it an appropriate surrogate in multiple sclerosis? Eur J Neurol. (2018) 25:1107–e101. doi: 10.1111/ene.13669, PMID: PubMed DOI PMC

Pandit L. No evidence of disease activity (NEDA) in multiple sclerosis – shifting the goal posts. Ann Indian Acad Neurol. (2019) 22:261–3. doi: 10.4103/aian.AIAN_159_19, PMID: PubMed DOI PMC

Ontaneda D, Thompson AJ, Fox RJ, Cohen JA. Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. Lancet. (2017) 389:1357–66. doi: 10.1016/S0140-6736(16)31320-4, PMID: PubMed DOI

Cree BAC, Cutter G, Wolinsky JS, Freedman MS, Comi G, Giovannoni G, et al. . Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. (2020) 19:988–97. doi: 10.1016/S1474-4422(20)30347-1, PMID: PubMed DOI

Block VJ, Lizée A, Crabtree-Hartman E, Bevan CJ, Grave SJS, Bove R, et al. . Continuous daily assessment of multiple sclerosis disability using remote step count monitoring. J Neurol. (2017) 264:316–26. doi: 10.1007/s00415-016-8334-6, PMID: PubMed DOI PMC

Block VJ, Bove R, Zhao C, Garcha P, Graves J, Romeo AR, et al. . Association of Continuous Assessment of step count by remote monitoring with disability progression among adults with multiple sclerosis. JAMA Netw Open. (2019) 2:e190570. doi: 10.1001/jamanetworkopen.2019.0570, PMID: PubMed DOI PMC

Block VJ, Pitsch EA, Gopal A, Zhao C, Pletcher MJ, Marcus GM, et al. . Identifying falls remotely in people with multiple sclerosis. J Neurol. (2022) 269:1889–98. doi: 10.1007/s00415-021-10743-y PubMed DOI PMC

Giannì C, Prosperini L, Jonsdottir J, Cattaneo D. A systematic review of factors associated with accidental falls in people with multiple sclerosis: a meta-analytic approach. Clin Rehabil. (2014) 28:704–16. doi: 10.1177/0269215513517575, PMID: PubMed DOI

Cameron MH, Thielman E, Mazumder R, Bourdette D. Predicting falls in people with multiple sclerosis: fall history is as accurate as more complex measures. Mult Scler Int. (2013) 2013:496325: 1–7. doi: 10.1155/2013/496325 PubMed DOI PMC

Nourbakhsh B, Revirajan N, Morris B, Cordano C, Creasman J, Manguinao M, et al. . Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. Lancet Neurol. (2021) 20:38–48. doi: 10.1016/S1474-4422(20)30354-9, PMID: PubMed DOI PMC

Kamudoni P, Johns J, Cook KF, Salem R, Salek S, Raab J, et al. . A comparison of the measurement properties of the PROMIS fatigue (MS) 8a against legacy fatigue questionnaires. Mult Scler Relat Disord. (2022) 66:104048. doi: 10.1016/j.msard.2022.104048, PMID: PubMed DOI

Block VJ, Bove R, Nourbakhsh B. The Role of Remote Monitoring in Evaluating Fatigue in Multiple Sclerosis: A Review. Front Neurol. (2022) 13:878313. doi: 10.3389/fneur.2022.878313 PubMed DOI PMC

Bergmann C, Becker S, Watts A, Sullivan C, Wilken J, Golan D, et al. . Multiple sclerosis and quality of life: the role of cognitive impairment on quality of life in people with multiple sclerosis. Mult Scler Relat Disord. (2023) 79:104966. doi: 10.1016/j.msard.2023.104966, PMID: PubMed DOI

London F, De Haan A, Benyahia Z, Landenne G, Duprez T, van Pesch V, et al. . Cognitive trajectories in relapsing-remitting multiple sclerosis: evidence of multiple evolutionary trends. Mult Scler Relat Disord. (2023) 77:104848. doi: 10.1016/j.msard.2023.104848, PMID: PubMed DOI

London F, El Sankari S, De Haan A, Benyahia Z, Landenne G, Duprez T, et al. . Patient-reported outcome measurements in a selective cohort of relapsing-remitting multiple sclerosis patients: relationships with physical disability, cognitive impairment, and MRI-derived metrics. Acta Neurol Belg. (2023) 123:1049–59. doi: 10.1007/s13760-023-02225-x, PMID: PubMed DOI

Theodorsdottir A, Nielsen HH, Ravnborg MH, Illes Z. Patient reported outcomes in a secondary progressive MS cohort related to cognition, MRI and physical outcomes. Mult Scler Relat Disord. (2023) 71:104550. doi: 10.1016/j.msard.2023.104550 PubMed DOI

Van Geel F, Geurts E, Abasıyanık Z, Coninx K, Feys P. Feasibility study of a 10-week community-based program using the WalkWithMe application on physical activity, walking, fatigue and cognition in persons with multiple sclerosis. Mult Scler Relat Disord. (2020) 42:102067. doi: 10.1016/j.msard.2020.102067, PMID: PubMed DOI

Pöttgen J, Friede T, Lau S, Gold SM, Letsch C, Bender G, et al. . Managing neuropsychological impairment in multiple sclerosis – controlled study on a standardized metacognitive intervention (MaTiMS). Mult Scler Relat Disord. (2022) 59:103687. doi: 10.1016/j.msard.2022.103687, PMID: PubMed DOI

Green R, Kalina J, Ford R, Pandey K, Kister I. SymptoMScreen: a tool for rapid assessment of symptom severity in MS across multiple domains. Appl Neuropsychol Adult. (2017) 24:183–9. doi: 10.1080/23279095.2015.1125905, PMID: PubMed DOI

Fitzgerald KC, Salter A, Tyry T, Fox RJ, Cutter G, Mowry EM, et al. . Validation of the SymptoMScreen with performance-based or clinician-assessed outcomes. Mult Scler Relat Disord. (2019) 29:86–93. doi: 10.1016/j.msard.2019.01.031 PubMed DOI

Kister I, Benedict R, Comi G, Cutter G, Guevaram CO, Clinch S, et al. . Fatigue and other patient-reported outcomes in patients with RRMS who switched to Ocrelizumab: 4-year data from CASTING-LIBERTO (P6-3.010). Neurology. (2023) 100:2199. doi: 10.1212/WNL.0000000000202199 DOI

Rau D, Müller B, Übler S. Evaluation of patient-reported outcomes in patients with relapsing multiple sclerosis treated with Cladribine tablets in the CLAWIR study: 12-month interim analysis. Adv Ther. (2023) 40:5547–56. doi: 10.1007/s12325-023-02682-z, PMID: PubMed DOI PMC

Moccia M, Fontana L, Palladino R, Falco F, Finiello F, Fedele M, et al. . Determinants of early working impairments in multiple sclerosis. Front Neurol. (2022) 13:1062847. doi: 10.3389/fneur.2022.1062847, PMID: PubMed DOI PMC

Neuberger EE, Abbass IM, Jones E, Engmann NJ. Work productivity outcomes associated with Ocrelizumab compared with other disease-modifying therapies for multiple sclerosis. Neurol Ther. (2021) 10:183–96. doi: 10.1007/s40120-020-00224-1, PMID: PubMed DOI PMC

Lerede A, Rodgers J, Middleton RM, Hampshire A, Nicholas R. Patient-reported outcomes in multiple sclerosis: a prospective registry cohort study. Brain Commun. (2023) 5:fcad199. doi: 10.1093/braincomms/fcad199 PubMed DOI PMC

Pesarin F, Salmaso L. The permutation testing approach: a review. Statistica. (2010) 70:481–509. doi: 10.6092/issn.1973-2201/3599 DOI

Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The multiple sclerosis impact scale (MSIS-29): a new patient-based outcome measure. Brain. (2001) 124:962–73. doi: 10.1093/brain/124.5.962, PMID: PubMed DOI

Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Measuring the impact of MS on walking ability: the 12-item MS walking scale (MSWS-12). Neurology. (2003) 60:31–6. doi: 10.1212/wnl.60.1.31 PubMed DOI

Grange E, Solaro C, Di Giovanni R, Marengo D. The correlation between 9-HPT and patient-reported measures of upper limb function in multiple sclerosis: a systematic review and meta-analysis. J Neurol. (2023) 270:4179–91. doi: 10.1007/s00415-023-11801-3, PMID: PubMed DOI PMC

Hillert J, Stawiarz L. The Swedish MS registry – clinical support tool and scientific resource. Acta Neurol Scand. (2015) 132:11–9. doi: 10.1111/ane.12425, PMID: PubMed DOI PMC

Murley C, Friberg E, Hillert J, Alexanderson K, Yang F. Validation of multiple sclerosis diagnoses in the Swedish National Patient Register. Eur J Epidemiol. (2019) 34:1161–9. doi: 10.1007/s10654-019-00558-7, PMID: PubMed DOI PMC

Alping P, Piehl F, Langer-Gould A, Frisell T. Validation of the Swedish multiple sclerosis register: further improving a resource for Pharmacoepidemiologic evaluations. Epidemiology. (2019) 30:230–3. doi: 10.1097/EDE.0000000000000948, PMID: PubMed DOI PMC

He A, Spelman T, Manouchehrinia A, Ciccarelli O, Hillert J, McKay K. Association between early treatment of multiple sclerosis and patient-reported outcomes: a nationwide observational cohort study. J Neurol Neurosurg Psychiatry. (2023) 94:284–9. doi: 10.1136/jnnp-2022-330169, PMID: PubMed DOI PMC

Boström I, Stawiarz L, Landtblom AM. Age-specific sex ratio of multiple sclerosis in the National Swedish MS register (SMSreg). Mult Scler. (2014) 20:513–4. doi: 10.1177/1352458513498636, PMID: PubMed DOI

Boström I, Stawiarz L, Landtblom AM. Sex ratio of multiple sclerosis in the National Swedish MS register (SMSreg). Mult Scler. (2013) 19:46–52. doi: 10.1177/1352458512446169 PubMed DOI

Trojano M, Liguori M, Paolicelli D, Zimatore GB, De Robertis F, Avolio C, et al. . Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in Southern Italy. Mult Scler. (2003) 9:451–7. doi: 10.1191/1352458503ms948oa, PMID: PubMed DOI

Trojano M, Bergamaschi R, Amato MP, Comi G, Ghezzi A, Lepore V, et al. . The Italian multiple sclerosis register. Neurol Sci. (2019) 40:155–65. doi: 10.1007/s10072-018-3610-0, PMID: PubMed DOI PMC

Filippi M, Tedeschi G, Pantano P, De Stefano N, Zaratin P, Rocca MA. The Italian Neuroimaging network initiative (INNI): enabling the use of advanced MRI techniques in patients with MS. Neurol Sci. (2017) 38:1029–38. doi: 10.1007/s10072-017-2903-z, PMID: PubMed DOI

Barizzone N, Zara I, Sorosina M, Lupoli S, Porcu E, Pitzalis M, et al. . The burden of multiple sclerosis variants in continental Italians and Sardinians. Mult Scler. (2015) 21:1385–95. doi: 10.1177/1352458515596599, PMID: PubMed DOI

Schiavetti I, Carmisciano L, Ponzano M, Cordioli C, Cocco E, Marfia GA, et al. . Signs and symptoms of COVID-19 in patients with multiple sclerosis. Eur J Neurol. (2022) 29:3728–36. doi: 10.1111/ene.15554, PMID: PubMed DOI PMC

Brichetto G, Monti Bragadin M, Fiorini S, Battaglia MA, Konrad G, Ponzio M, et al. . The hidden information in patient-reported outcomes and clinician-assessed outcomes: multiple sclerosis as a proof of concept of a machine learning approach. Neurol Sci. (2020) 41:459–62. doi: 10.1007/s10072-019-04093-x, PMID: PubMed DOI PMC

Zaratin P, Khan U, Graffigna G. Comment on “reflections on patient engagement by patient partners: how it can go wrong”. Res Involv Engag. (2023) 9:122. doi: 10.1186/s40900-023-00534-2, PMID: PubMed DOI PMC

Van Hecke W, Costers L, Descamps A, Ribbens A, Nagels G, Smeets D, et al. . A novel digital care management platform to monitor clinical and subclinical disease activity in multiple sclerosis. Brain Sci. (2021) 11:1171. doi: 10.3390/brainsci11091171, PMID: PubMed DOI PMC

Mikolaizak AS, Rochester L, Maetzler W, Sharrack B, Demeyer H, Mazzà C, et al. . Connecting real-world digital mobility assessment to clinical outcomes for regulatory and clinical endorsement-the Mobilise-D study protocol. PLoS One. (2022) 17:e0269615. doi: 10.1371/journal.pone.0269615. eCollection 2022, PMID: PubMed DOI PMC

Midaglia L, Mulero P, Montalban X, Graves J, Hauser SL, Julian L, et al. . Adherence and satisfaction of smartphone- and smartwatch-based remote active testing and passive monitoring in people with multiple sclerosis: nonrandomized interventional feasibility study. J Med Internet Res. (2019) 21:e14863. doi: 10.2196/14863, PMID: PubMed DOI PMC

Polhemus A, Ortiz LD, Brittain G, Chynkiamis N, Salis F, Gaßner H, et al. . Walking on common ground: a cross-disciplinary scoping review on the clinical utility of digital mobility outcomes. NPJ Digit Med. (2021) 4:149. doi: 10.1038/s41746-021-00513-5, PMID: PubMed DOI PMC

Keogh A, Mc Ardle R, Diaconu MG, Ammour N, Arnera V, Balzani F, et al. . Mobilizing patient and public involvement in the development of real-world digital technology solutions: tutorial. J Med Internet Res. (2023) 25:e44206. doi: 10.2196/44206, PMID: PubMed DOI PMC

Oh J, Capezzuto L, Kriara L, Schjodt-Eriksen J, van Beek J, Bernasconi C, et al. . Use of smartphone-based remote assessments of multiple sclerosis in floodlight open, a global, prospective, open-access study. Sci Rep. (2024) 14:122. doi: 10.1038/s41598-023-49299-4, PMID: PubMed DOI PMC

Rinderknecht MD, Zanon M, Boonstra TA, Angelini L, Stanev D, Chan GG, et al. . An observational study to assess validity and reliability of smartphone sensor-based gait and balance assessments in multiple sclerosis: floodlight GaitLab protocol. Digit Health. (2023) 9:20552076231205284. doi: 10.1177/20552076231205284, PMID: PubMed DOI PMC

Bouleau A, Dulong C, Schwerer CA, Delgrange R, Bouaou K, Brochu T, et al. . The socioeconomic impact of multiple sclerosis in France: Results from the PETALS study. Mult Scler J Exp Transl Clin. (2022) 21:8–20552173221093219. doi: 10.1177/2055217322109321960, PMID: PubMed DOI PMC

Tanoh IC, Maillart E, Labauge P, Cohen M, Maarouf A, Vukusic S, et al. . MSCopilot: New smartphone-based digital biomarkers correlate with Expanded Disability Status Scale scores in people with Multiple Sclerosis. Mult Scler Relat Disord. (2021) 55:103164. doi: 10.1016/j.msard.2021.103164.61, PMID: PubMed DOI

Maillart E, Labauge P, Cohen M, Maarouf A, Vukusic S, Donzé C, et al. . MSCopilot, a new multiple sclerosis self-assessment digital solution: results of a comparative study versus standard tests. Eur J Neurol. (2020) 27:429–436. doi: 10.1111/ene.14091, PMID: PubMed DOI

Fukuda M, Sakamaki K, Oba K. The net benefit for time-to-event outcome in oncology clinical trials with treatment switching. Clin Trials. (2023) 20:670–80. doi: 10.1177/17407745231186081, PMID: PubMed DOI

Péron J, Roy P, Ozenne B, Roche L, Buyse M. The net chance of a longer survival as a patient-oriented measure of treatment benefit in randomized clinical trials. JAMA Oncol. (2016) 2:901–5. doi: 10.1001/jamaoncol.2015.6359, PMID: PubMed DOI